Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

12 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    A, Tumor growth curves from the initial sunitinib drug trials, with endpoint set at 1,300 mm3 (mean ± SEM). Measurements began one week after tumor inoculation and on the day sunitinib treatment began. Subsequent experimental endpoints were set on the basis of these growth curves and their intersections with this data are shown. B, Histogram plot showing the distribution of tumor sizes at day 8 of treatment. Sunitinib-treated tumors exceeding 250 mm3 in size were identified as falling into the nonresponsive cohort. Sunitinib treatment significantly retards growth of responsive tumors.

    Cancer Res, 2017, 77(4):1008-1020 . Sunitinib Malate purchased from Selleck.

  • Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 M1q2Z2tqdmG|ZTDBd5NigQ>? NHzsTJdKdmirYnn0bY9vKG:oIGDES2YucW6mdXPl[EBDemSXIHnuZ49zeG:{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= NUW5cGtSOTJ4NE[wNVk>
3T3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPSZpo6UW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhcW6mdXPl[EA{XDNiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjBzIN88US=> M{Pr[FEzPjR4MEG5
3T3 MnvISpVv[3Srb36gRZN{[Xl? MXPJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5Ihf2m2aDDJR|UxKG:oIECuNFUh|ryP M33P[FEzPjR4MEG5
3T3 NV\oNWZ7U2mwYYPlJGF{e2G7 M{j3O|IxKG2rbh?= MVzEUXNQ NUXFe3RWS2WubIXsZZIhcW6qaXLpeIlwdiCxZjDWSWdHKGmwZIXj[YQhcHWvYX6gT2RTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNlIh|ryP MWSxOlE3OjByOB?=
NIH3T3 NVfsVXY{U2mwYYPlJGF{e2G7 Ml7WNlAhdWmw Mk\ZSG1UVw>? NHnySW9qdmirYnn0JIh2dWGwIFvEVkBscW6jc3Wg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkCxPEDPxE1? NGrXfVUyPjF4MkCwPC=>
A549 NEOzRllHfW6ldHnvckBCe3OjeR?= M{HXU2ROW09? M3\KeWlvcGmkaYTpc44hd2ZiYz3N[ZQh\GWyZX7k[Y51KEiJRj3pcoR2[2WmIHj1cYFvKEF3NEmgZ4VtdCCvaXfyZZRqd25id3n0bEBKSzVyIH;mJFIh|ryP MXuxPFQ{PDF2NR?=
DU145 MXTGeY5kfGmxbjDBd5NigQ>? NFXyZ|NFVVOR NU\NTIJwUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iRGWxOFUh[2WubDDzZ4F1fGW{aX7nJJdqfGhiSVO1NEBw\iBzMDFOwG0> NIXVdVkyQDR|NEG0OS=>
KB3-1 MknsR5l1d3SxeHnjJGF{e2G7 M3L2[|czKGh? M3TWZmROW09? NGS4Xm5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeyLX7l[4F1cX[nIFvCMVMuOSClZXzsd{B4cXSqIFnDOVAhd2ZiMj6zJO69VQ>? NFO5RmUyQTN7N{OyNi=>
KBV1 MVvDfZRwfG:6aXOgRZN{[Xl? MojuO|IhcA>? NHnycnJFVVOR MmXBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVE1odHmlb4Dyc5RmcW5vZYjwdoV{e2mwZzDLRnYyKGOnbHzzJJdqfGhiSVO1NEBw\iB2LkGg{txO MmjYNVk{QTd|MkK=
A375 MXPDfZRwfG:6aXOgRZN{[Xl? MkTaO|IhcA>? NGDtRVBFVVOR M1;3Z2lEPTB;NT60JO69VQ>? NF[2SXYyQTZ3NESwPC=>
RS4-11 M{\rdGZ2dmO2aX;uJGF{e2G7 NXToOGpVOiCq NXnp[mJ6UW6qaXLpeIlwdiCxZjDGUHQ{KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB7OTFOwG0> NYTXVHI5OTl4NUS0NFg>
RS4-11 MmHwSpVv[3Srb36gRZN{[Xl? M3;oOFIhcA>? NEnHUIdKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB|NDFOwG0> NYT4eIdNOTl4NUS0NFg>
Sf9 MoD0T4lv[XOnIFHzd4F6 M2fLZVMxKG2rbh?= NI\Xc2dKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgWmVITlJiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjF6NTFOwG0> NGXG[5cyQTh3NEC1NS=>
Ba/F3 M1u5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonOO|IhcA>? MmP4TWM2OD1zLkKg{txO NFXXfm8zODFzN{CwOC=>
BaPTC2 NYnuUnBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLpO|IhcA>? NWnlfWFTUUN3ME2wMlIzKM7:TR?= NHm4ZXYzODFzN{CwOC=>
Sf9 NWrWNIZsTnWwY4Tpc44hSXO|YYm= NF\VbVkyKGh? MnjWSG1UVw>? MmTVTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIGLFWEBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEGuN{DPxE1? NVTufW5SOjBzMUewNFQ>
H4 NEPzT|ZEgXSxdH;4bYMhSXO|YYm= MXSxNEDPxE1? NUXCOXJRXG:6aXPpeJkhcW5iaIXtZY4hUDRiY3XscJM> NUfBNWF{OjB|NUC4NFY>
SF-539 M{fGcGtqdmG|ZTDBd5NigQ>? MXWzN|Mh|ryP NHLWdpE3OCCvaX6= MneySG1UVw>? MYTJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGyMlIh|ryP NEXiN2EzODRyM{ewNC=>
U251 MXHLbY5ie2ViQYPzZZk> NXzObXhwOzN|IN88US=> NWX3PFVRPjBibXnu M2TVTWROW09? MkDDTY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzOD65JO69VQ>? MkXsNlA1ODN5MEC=
A431 NH7ZcVRMcW6jc3WgRZN{[Xl? MV;Jcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEzNjJizszN NXHZN|Q5OjB3NUiwO|I>
A431 M1j3XmtqdmG|ZTDBd5NigQ>? NFP4d3NKdmirYnn0bY9vKG:oIG\FS2ZTOiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFE5NjlizszN NHSwWnIzODV3OEC3Ni=>
HepG2 NFjscVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP6T3BPPzJiaB?= NGjYVW1KSzVyPUOuPFEh|ryP NX\vOG1iOjB3N{C1NlY>
Kasumi-1 NHTF[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS3NkBp MWPJR|UxRTBwMEG2JO69VQ>? NFe5SIUzODV5MEWyOi=>
RS4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;lO|IhcA>? MlX6TWM2OD1zIN88US=> NIfIeGgzODV5MEWyOi=>
THP1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[wO|IhcA>? M3TFXmlEPTB;MD61JO69VQ>? NEPR[JAzODV5MEWyOi=>
Kasumi-1 NVjoZ3FXTnWwY4Tpc44hSXO|YYm= NXzKWlN4UW6qaXLpeIlwdiCxZjDjMWtqfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0> MX2yNFg{OzB|OR?=
A549 NXvLdoU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHXXJYyPiCq NUH2XHN1SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsdy=> NFrTWHozOTR3MES2Ny=>
HL60 NGXne3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTmNVYhcA>? NWfmblZlSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsdy=> NHG3U5MzOTR3MES2Ny=>
HUVEC NYr3UFJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixOkBp NVPxeWVVUW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCyMlc2KM7:TR?= MUWyNVQ2ODR4Mx?=
HUVEC NVXFelVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P6cVE3KGh? MXTJcohq[mm2aX;uJI9nKGKIR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDRwMESg{txO MWCyNVQ2ODR4Mx?=
IM9 M3v3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjYWpIyPiCq NWr5TJFoSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz MnrNNlE1PTB2NkO=
K562 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jyXlE3KGh? NHPDWmZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzz NV7Zcoh1OjF2NUC0OlM>
MDA-MB-231 NWjBNJhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxOkBp MXPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{ NUHPc4lpOjF2NUC0OlM>
H460 NEnmdlVEgXSxdH;4bYMhSXO|YYm= NWnETndTPzJiaB?= NUG3[GNZUUN3ME2yMlch|ryP MUGyNVYzOTh6MB?=
SMMC7721 MWLDfZRwfG:6aXOgRZN{[Xl? M4f6TlczKGh? MX\JR|UxRTZwNEeg{txO M1zE[FIyPjJzOEiw
WI38 M4DZ[WN6fG:2b4jpZ{BCe3OjeR?= Moq2O|IhcA>? NVT1TZJQUUN3ME24MlU3KM7:TR?= MmLBNlE3OjF6OEC=
HEK293 MnfnT4lv[XOnIFHzd4F6 NYPESIo3OTByIH7N MXSxJIg> MmKy[I9meyCwb4SgbY5pcWKrdDDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjD0fZJwe2mwZTCxNVc2KHKnc3nkeYUhd25iVlXHSnIzKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJM> NU\XZYVvOjF6OEWyPFc>
HUVEC NHTMWJBHfW6ldHnvckBCe3OjeR?= NYXYRnp1OSEQvF2= MXKyOEBp NW[3N|d5SW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iVlXHSk1qdmS3Y3XkJINmdGxibXnndoF1cW:w M3HTOVIyQTZ|M{C1
HUVEC M1fITGZ2dmO2aX;uJGF{e2G7 M2jINlEh|ryP NYrVcoJjOSCq MlzKTY5pcWKrdHnvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejJyMj;UfZIzODRiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE MWqyNVk3OzNyNR?=
HUVEC MmruSpVv[3Srb36gRZN{[Xl? MkHFNUDPxE1? NVS3e2tUOSCq NXnkVVZIUW6qaXLpeIlwdiCxZjDlUm9UKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtNVE4OiCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> M{XkfVIyQTZ|M{C1
HUVEC NVnjO41pU2mwYYPlJGF{e2G7 M2rMWFEh|ryP MUCxJIg> Mk[3TY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJIF1KHS7cj2xNVc2KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> NETlNXEzOTl4M{OwOS=>
HUVEC NFLLfnJHfW6ldHnvckBCe3OjeR?= M{LVZVEh|ryP MVyxJIg> M3LUT4Rw\XNibn;0JIlvcGmkaYSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtOFc{KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> NYDje4tiOjF7NkOzNFU>
HL60 MlH5R5l1d3SxeHnjJGF{e2G7 NH7CcW42OCEQvF2= MlT3OFghcA>? NFHzTWVFVVOR M2fvZWlEPTB;MUWuOUDPxE1? NX3kdlVEOjJyMUmxPFg>
K562 NGj6PJVEgXSxdH;4bYMhSXO|YYm= NF;1N4I2OCEQvF2= MmnROFghcA>? NUjFblNwTE2VTx?= NIHLTJJKSzVyPUKxMlkh|ryP M3LEclIzODF7MUi4
PC3 NUKxVJRRS3m2b4TvfIlkKEG|c3H5 MmPoOVAh|ryP NVfxSol1PDhiaB?= M1zRZWROW09? NWXmU2p7UUN3ME2yOU4yKM7:TR?= MUWyNlAyQTF6OB?=
SF-539 MWrLbY5ie2ViQYPzZZk> MW[zN|Mh|ryP NHLLTIg3OCCvaX6= NX\4PXNsUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgeJlzd3OrbnWgb4lv[XOnIHHjeIl3cXS7IHnuJHBFT0ZvQlKtd5RqdXWuYYTl[EBpfW2jbjDTSk02OzliY3XscJMhf2m2aDDJR|UxKG:oIEGyMlIh|ryP MWWyNlIxPDd2MR?=
HAEC MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPPU40yODBizszN NUfSSVFnPzJiaB?= NVnZSVRTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIRWVEKGOnbHzzJIV5eHKnc4PpcochXkWJRmKge4l1cCCLQ{WwJI9nKDBwMTFOwG0> M{TKTlIzPDR2Nke5
HT-29 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLrNVAxKM7:TR?= MXK3NkBp Ml23RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDlfJBz\XO|aX7nJHZGT0[UIIfpeIghUUN3MDDv[kAxNjN|IN88US=> NFz1fXQzOjR2NE[3PS=>
MV4-11 M1fCc2N6fG:2b4jpZ{BCe3OjeR?= MmrCO|IhcA>? MmjBTWM2OD1yLkCwN{DPxE1? NF7kcXIzOjR3MkWxPC=>
HepG2 MXrDfZRwfG:6aXOgRZN{[Xl? MkDKOFghcA>? NHXzZ3lKSzVyPUGzMlI1KM7:TR?= MWiyNlQ5OzZyOB?=
PC9 NVLvVVVDS3m2b4TvfIlkKEG|c3H5 MYS0PEBp M2qzN2lEPTB;MUCuPVch|ryP MXGyNlQ5OzZyOB?=
CAKI-1 M2PTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fwblExOCEQvF2= M13yNlQ5KGh? MoDYSG1UVw>? NGLjXo5IUTVyPUCuOlMh|ryP MXiyNlU3ODZ{Nx?=
EKVX MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjlSnd7OTByIN88US=> MXi0PEBp NF\kbHZFVVOR M4nZWmdKPTB;Nz65JO69VQ>? MWKyNlU3ODZ{Nx?=
MCF7 M4DmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnKb492OTByIN88US=> M2nqdlQ5KGh? NFvu[IpFVVOR NUHCdVR{T0l3MU2yJO69VQ>? NW\nOVdVOjJ3NkC2Nlc>
MDA-MB-435 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T6dlExOCEQvF2= M3;JO|Q5KGh? NEmxS5JFVVOR M4\r[2dKPTJ;MjFOwG0> MV[yNlU3ODZ{Nx?=
OVCAR3 NXfyTnczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\pUVExOCEQvF2= MnL2OFghcA>? NVjTN|RrTE2VTx?= NV3iZWdbT0l3M{2zMlIh|ryP NG\pOoozOjV4ME[yOy=>
SNB19 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi0OlhPOTByIN88US=> NETFTJQ1QCCq Mmr3SG1UVw>? Mnm4S2k2PD1zMDFOwG0> NIfZV|IzOjV4ME[yOy=>
SW620 M2f6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3JfoQyODBizszN MlL2OFghcA>? M{\6fmROW09? MXPHTVU2RTFwMzFOwG0> MYKyNlU3ODZ{Nx?=
TK10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe0SYIyODBizszN M2TBS|Q5KGh? NW\SNJBHTE2VTx?= NHLDWW1IUTV4PU[uN{DPxE1? MnTYNlI2PjB4Mke=
UACC257 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW5ZnVyOTByIN88US=> MWG0PEBp NF3RbVVFVVOR MnrFS2k2Pz12IN88US=> Ml;jNlI2PjB4Mke=
HAEC MmT1R5l1d3SxeHnjJGF{e2G7 NVnYPGwxOTByIN88US=> NUXmc4NuPzJiaB?= M37XUWROW09? MnTrR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BJSUWFIIfpeIghUUN3MDDv[kAxNjFizszN MX2yN|E{OTV2MR?=
HT-29 M33sPWN6fG:2b4jpZ{BCe3OjeR?= MWKxNFAh|ryP MV63NkBp M3LwPGROW09? MkPTR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BpfW2jbjDIWE0zQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? M33JSFI{OTNzNUSx
HCT116 NYm0XmJyTnWwY4Tpc44hSXO|YYm= M2Kwd|I1KGh? M4DsTmROW09? NX;IdZZTSW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwhdWmpcnH0bY9v MUiyN|E2OzJyMB?=
HUVEC MW\GeY5kfGmxbjDBd5NigQ>? MWqyJO69VQ>? NYT2dnJwOThiaB?= M4jTb2ROW09? MnjBRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUO|IIXu[IVzKGi7cH;4bYMh[2:wZHn0bY9vKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfHWkZTDmc5Ju[XSrb36= M2XxUVI{OTV|MkCw
ACHN Mn63R5l1d3SxeHnjJGF{e2G7 MlPKOkBl MUfJR|UxRTJwNTFOwG0> Moe2NlM{PjBzMES=
A498 NX7KfotsS3m2b4TvfIlkKEG|c3H5 MknCNVAxKM7:TR?= MoH3O|IhcA>? MVXEUXNQ Mn[yTWM2OD12LkOg{txO NGH4cWQzOzR6OU[yOi=>
HUVEC MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUizJO69VQ>? NInsSFEzPCCq MYTEUXNQ NHLkdINCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EB1fWKnIH\vdo1ifGmxbjD3bZRpKEWFNUCgc4YhOC54NEWg{txO MljkNlM2QDN7MUG=
HUVEC M4TiW2tqdmG|ZTDBd5NigQ>? MUGyNFAh|ryP MVzEUXNQ MYfJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36gbY4h\3Kxd4ToJIZi[3Sxcj3zeIlufWyjdHXkJGhWXkWF NGixUWQzOzV6M{mxNS=>
HUVEC Mn;WT4lv[XOnIFHzd4F6 MnrDNlAxKM7:TR?= NFziO5hFVVOR M2DLUmlvcGmkaYTpc44hd2ZiVlXHSnIyKHCqb4PwbI9zgWyjdHnvckBqdiCpcn;3eIgh\mGldH;yMZN1cW23bHH0[YQhUFWYRVO= M1;uT|I{PTh|OUGx
A549 MoLiR5l1d3SxeHnjJGF{e2G7 NEnHRXA4OiCq M3fES2ROW09? Mn\1TWM2OD1{LkS0JO69VQ>? NGTvepUzOzZyMkS0NS=>
HCT116 MmrPR5l1d3SxeHnjJGF{e2G7 MYO3NkBp MmCwSG1UVw>? MXLJR|UxRTRwN{Gg{txO MlHoNlM3ODJ2NEG=
MCF7 MmrSR5l1d3SxeHnjJGF{e2G7 NEHPTIg4OiCq NHTuRWxFVVOR NXrUVmh6UUN3ME22MlI6KM7:TR?= MXOyN|YxOjR2MR?=
BGC NUTSXGtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHxOZU4OiCq NUTpZ2R4TE2VTx?= M{TnfmlEPTB;ND63PEDPxE1? M{j0bVI{QTl7MESw
BxPC3 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TpPVczKGh? NUDHfIl3TE2VTx?= M1zyfmlEPTB;Mz62N{DPxE1? MoXVNlM6QTlyNEC=
HT-29 NHH1ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\PO|IhcA>? NXjRXIlJTE2VTx?= MWDJR|UxRTFwNEeg{txO NGjYS|UzOzl7OUC0NC=>
T24 Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknMO|IhcA>? MmX1SG1UVw>? NGHWVnNKSzVyPUKuOFQh|ryP NG\N[4wzOzl7OUC0NC=>
4T1 NFnPb|FEgXSxdH;4bYMhSXO|YYm= Ml3pO|IhcA>? NV3veI83TE2VTx?= MWnJR|UxRTBwMEG2JO69VQ>? NVXZdoRwOjR6OUC2OVI>
MCF7 MU\DfZRwfG:6aXOgRZN{[Xl? M{\xb|czKGh? NIDzUpRFVVOR MXfJR|UxRTBwMEK3NUDPxE1? NF3kV5EzPDh7ME[1Ni=>
MCF7 NYHveXJMS3m2b4TvfIlkKEG|c3H5 MmqwO|IhcA>? M2rMZWROW09? M{e5V2lEPTB;MD6wNlk{KM7:TR?= M2n5XlI1QDlyNkWy
MDA-MB-231 MnrHR5l1d3SxeHnjJGF{e2G7 MWW3NkBp NWPKNnFlTE2VTx?= NXPDcoF{UUN3ME2wMlAzOjNizszN MWCyOFg6ODZ3Mh?=
MDA-MB-435 NWDrTXZSS3m2b4TvfIlkKEG|c3H5 NVrHPVZPPzJiaB?= NYTTZpN{TE2VTx?= NVG0ZYI3UUN3ME2wMlAxQTdizszN MV2yOFg6ODZ3Mh?=
MDA-MB-468 M2nRdGN6fG:2b4jpZ{BCe3OjeR?= NVn5T|ZbPzJiaB?= M3judmROW09? NVvTbZRXUUN3ME2wMlAxPjFizszN M2nx[lI1QDlyNkWy
A431 NEnUUmZMcW6jc3WgRZN{[Xl? M2n2PVExKM7:TR?= M3XhOVEhcA>? NYXzeFRKTE2VTx?= Ml;aTY5pcWKrdHnvckBw\iCHR1\SJJdqfGhiSVO1NEBw\iByLkG3NlEh|ryP Mk\INlQ5QTB4NUK=
SH-SY5Y MVzLbY5ie2ViQYPzZZk> NXLEZlBMOTBizszN M17TR|EhcA>? NF\XUVVFVVOR NVXPWYRMUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGge4l1cCCLQ{WwJI9nKDBwMEizNUDPxE1? Ml7GNlQ5QTB4NUK=
U251 MlTCT4lv[XOnIFHzd4F6 NHf1[oIyOCEQvF2= MV[xJIg> M4fiNmROW09? NHvuT4dKdmirYnn0bY9vKG:oIG\FS2ZTOiC5aYToJGlEPTBib3[gNE4xOTh7IN88US=> M{nW[lI1QDlyNkWy
Bel7402 NFyxfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\hOVczKGh? MkP0SG1UVw>? M3W2PWlEPTB;Mj62O{DPxE1? NYfielBqOjR7MES5OlE>
HK2 M{PLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvYO|IhcA>? NXm0TXFZTE2VTx?= NHHVXmdKSzVyPUWuPFUh|ryP MVOyOFkxPDl4MR?=
LO2 M4\nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG5dZI4OiCq Ml;WSG1UVw>? NEX1SYNKSzVyPUG5Mlk{KM7:TR?= MljxNlQ6ODR7NkG=
MV4-11 M2S3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC0PEBp MknjSG1UVw>? MWfJR|UxRTBwMECzJO69VQ>? NYKxO5NtOjR7MES5OlE>
NCI-H3122 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nRS|czKGh? MXTEUXNQ Mn7wTWM2OD1yLkizJO69VQ>? NIX3[o4zPDlyNEm2NS=>
NCI-H460 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPzTlk4OiCq MX7EUXNQ NYTtfoZFUUN3ME20MlMyKM7:TR?= NVrXemVPOjR7MES5OlE>
NCI-H526 M{LEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3nO|IhcA>? NYTpOIF4TE2VTx?= MmXDTWM2OD1zLkCxJO69VQ>? M2jBZ|I1QTB2OU[x
TT Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm2Z|VFPzJiaB?= NYTudWNzTE2VTx?= MWfJR|UxRTBwMESg{txO MVuyOFkxPDl4MR?=
EoL-1-cell MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\NTWM2OD1zLk[0JJBO NYX1Oo1bW0GQR1XS
MV-4-11 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r2cmlEPTB;MkeyJJBO MmHCV2FPT0WU
NOS-1 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjGU4I3UUN3ME2xOU4{KG6P NIW2WpdUSU6JRWK=
CGTH-W-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:1S2d[UUN3ME2zNE46PCCwTR?= M2XyV3NCVkeHUh?=
MONO-MAC-6 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrMTWM2OD1|Mz64JI5O M{XFNHNCVkeHUh?=
ALL-PO M3HWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq5TWM2OD15OT64PUBvVQ>? MXHTRW5ITVJ?
NKM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi1bVU4UUN3ME25PE42OiCwTR?= NEn6dmdUSU6JRWK=
KM12 NWPmN|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTHPG1uUUN3ME2zOVAvOTRibl2= NXvlZWlNW0GQR1XS
TE-15 NHX3fJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXnSmpKUUN3ME21NFcvPjFibl2= MoPLV2FPT0WU
697 NHO5N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZzND6yOUBvVQ>? MmHIV2FPT0WU
MOLT-16 M2XKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfwXY9yUUN3ME22N|EvOzJibl2= MmDWV2FPT0WU
GB-1 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLETWM2OD15MUCuNlMhdk1? NGfiXWtUSU6JRWK=
TE-12 M2PLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHpTWM2OD16MESuOVUhdk1? MmTiV2FPT0WU
ES6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[4WGlEPTB;OUixMlA3KG6P MnzwV2FPT0WU
LC-2-ad MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj3TWM2OD1zLkGxOFA4KM7:TR?= NGXWZYVUSU6JRWK=
BL-70 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fibmlEPTB;MT6xNVg1PiEQvF2= NI\ncZRUSU6JRWK=
ETK-1 M2DWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwMki1PEDPxE1? MVTTRW5ITVJ?
A4-Fuk MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHPZVVHUUN3ME2xMlM1OTRzIN88US=> MYrTRW5ITVJ?
OCI-AML2 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L3O2lEPTB;MT6zOlg2OSEQvF2= MWLTRW5ITVJ?
SIG-M5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwM{ewNFkh|ryP MYTTRW5ITVJ?
NCI-SNU-16 M{fHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fkcWlEPTB;MT60OlQ5PiEQvF2= NEfSNW5USU6JRWK=
PSN1 M1;1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fXSGlEPTB;MT61NFY4PiEQvF2= MYDTRW5ITVJ?
SR NXrQZppsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF70OY5KSzVyPUGuOVQ2PzJizszN NEjwPYlUSU6JRWK=
A3-KAW NUHEe5ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwNkK1OFYh|ryP M4jKe3NCVkeHUh?=
KS-1 NHnofmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjG[VVKSzVyPUGuOlkzPDdizszN NHjtT3FUSU6JRWK=
CTV-1 M4nvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL6cXdYUUN3ME2xMlczPzVzIN88US=> Ml\mV2FPT0WU
LB1047-RCC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjRb4drUUN3ME2xMlgyPjJ2IN88US=> MVvTRW5ITVJ?
EMG-01 NEHmXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC4Ulc1UUN3ME2xMlg{PTZ|IN88US=> MkTNV2FPT0WU
TE-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXr[VdbUUN3ME2xMlg{QTh3IN88US=> NVPBboNyW0GQR1XS
CMK NF3jS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwOUW1NVch|ryP NI\PWmtUSU6JRWK=
NB1 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3BXXU{UUN3ME2xMlk3OTF5IN88US=> MnTtV2FPT0WU
HAL-01 NE\nbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLYO|NXUUN3ME2yMlA2QTR4IN88US=> M1rSXHNCVkeHUh?=
DEL M4m1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwMEi0PFIh|ryP M{PGOHNCVkeHUh?=
RL95-2 NGHDb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDwc3dZUUN3ME2yMlEyOTN5IN88US=> NVnWNoI1W0GQR1XS
KARPAS-299 NXW0PG9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwMUGzNVMh|ryP NE\0VldUSU6JRWK=
EW-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfpTWM2OD1{LkGzOVA5KM7:TR?= M4nlXHNCVkeHUh?=
RS4-11 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPQfXpKSzVyPUKuNVc6OjRizszN Mk\SV2FPT0WU
BB30-HNC Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PhWGlEPTB;Mj6yNlM4PSEQvF2= MVLTRW5ITVJ?
DOHH-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GxPGlEPTB;Mj6zN|Q{OSEQvF2= MVjTRW5ITVJ?
RPMI-8402 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLVTWM2OD1{LkOzOlE5KM7:TR?= MljHV2FPT0WU
BV-173 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P2WWlEPTB;Mj6zN|Y3KM7:TR?= NX6zRWNtW0GQR1XS
TE-10 NFnLc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yycWlEPTB;Mj6zOFM5PCEQvF2= MoeyV2FPT0WU
TE-8 NHXibmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwM{ewN|gh|ryP M4f6PHNCVkeHUh?=
K052 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\S[FhKSzVyPUKuOFAzODJizszN NWnjR4tZW0GQR1XS
KARPAS-45 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn0TWM2OD1{LkS5OFQ3KM7:TR?= MlX2V2FPT0WU
SK-NEP-1 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj0dGdKSzVyPUKuOlAzOzdizszN MV3TRW5ITVJ?
KGN M{jaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDyTWM2OD1{Lk[wN|M6KM7:TR?= MoTmV2FPT0WU
ML-2 M2KwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm0SJRwUUN3ME2yMlY{PTF{IN88US=> M2r4VXNCVkeHUh?=
LAMA-84 M1XO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwNkm1OFUh|ryP MmDlV2FPT0WU
LXF-289 NYDJeG9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJ[GlEPTB;Mj63Nlk5QSEQvF2= M3PabXNCVkeHUh?=
A101D NHjlXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fHdWlEPTB;Mj63PFMxPCEQvF2= Mn;XV2FPT0WU
KY821 NXzzOGZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[4flZKSzVyPUKuO|k4PThizszN NHHOeI5USU6JRWK=
ES4 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLxTWM2OD1{LkiwOlI5KM7:TR?= M1zqWHNCVkeHUh?=
SCC-3 NHTifnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvPNIczUUN3ME2yMlgzQDlzIN88US=> MXLTRW5ITVJ?
NALM-6 NWTRW|hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwOUC0O|Mh|ryP NVy5bY1OW0GQR1XS
BL-41 NUHlRXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3oSXNnUUN3ME2yMlkyOjJ{IN88US=> MnvpV2FPT0WU
OPM-2 NHT4d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwMEW5OVQh|ryP MYTTRW5ITVJ?
SF126 M2jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPIZ49KSzVyPUOuNFYyQThizszN Ml7OV2FPT0WU
BE-13 NHq2OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKzTWM2OD1|LkKzNVEyKM7:TR?= MnjtV2FPT0WU
SF268 M4i4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTLTWM2OD1|LkOyPFY6KM7:TR?= M3jGeXNCVkeHUh?=
MOLT-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jqOWlEPTB;Mz6zPVg{QCEQvF2= MV\TRW5ITVJ?
PF-382 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFThenFKSzVyPUOuOFQ2PyEQvF2= NG\l[Y9USU6JRWK=
HEL MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwNEiwNFUh|ryP MnvSV2FPT0WU
RPMI-6666 NV;5eWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLhPHptUUN3ME2zMlU1OTdzIN88US=> NUjZZ|ZoW0GQR1XS
QIMR-WIL NWntPJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPNTWM2OD1|Lk[zN|kyKM7:TR?= MWjTRW5ITVJ?
ATN-1 M4nRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPBTWM2OD1|Lk[3NVE1KM7:TR?= MXLTRW5ITVJ?
BB49-HNC NWDUUXlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DTO2lEPTB;Mz63NFUxQCEQvF2= MU\TRW5ITVJ?
HCE-4 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwN{i2OFIh|ryP MWTTRW5ITVJ?
SK-LMS-1 M3LHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG3T3pKSzVyPUOuPFM{OzhizszN MlrTV2FPT0WU
MS-1 M1vwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPhPXpkUUN3ME2zMlg{Pzd6IN88US=> MUfTRW5ITVJ?
JAR NYXuc|dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHnV4ZKSzVyPUOuPVg5OzJizszN NXvx[4E3W0GQR1XS
KE-37 M1HMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPUTWM2OD12LkC2NVU5KM7:TR?= NYfGN2dLW0GQR1XS
LB996-RCC NWG5O5o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnreGhKSzVyPUSuNVIyPjhizszN NGXjO3lUSU6JRWK=
HH NYTDSVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nmVGlEPTB;ND6yNFkyPCEQvF2= MoLLV2FPT0WU
HL-60 NH\2dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrLTWM2OD12LkKxNFY2KM7:TR?= MnT5V2FPT0WU
HOP-62 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRwM{O1NkDPxE1? MnqyV2FPT0WU
NOMO-1 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTRwM{O2PVkh|ryP M{\JcnNCVkeHUh?=
DU-4475 NX3CT4prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjD[oJYUUN3ME20MlM3PzJ7IN88US=> MkiwV2FPT0WU
LC4-1 M{jlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnTTWM2OD12LkO4NFch|ryP MmPyV2FPT0WU
MC116 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nhXGlEPTB;ND60N|A5OSEQvF2= NVvTPWI4W0GQR1XS
SW982 M3fFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiyUpdKSzVyPUSuOVU{ODdizszN MXvTRW5ITVJ?
SK-N-DZ MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LoOWlEPTB;ND62O|A6QSEQvF2= Mm\OV2FPT0WU
EW-1 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDyS5VzUUN3ME20MlY4QTFzIN88US=> M4rUN3NCVkeHUh?=
SU-DHL-1 NUfBU4VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvKTWM2OD12LkiwNVc1KM7:TR?= NXX6TYF2W0GQR1XS
L-363 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLXWmdKSzVyPUSuPFA3OjFizszN NWfEeFFEW0GQR1XS
OS-RC-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRwOEezNUDPxE1? NX3VXmFrW0GQR1XS
HD-MY-Z NGTL[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKzVoJKSzVyPUWuNVc{ODFizszN MX;TRW5ITVJ?
MHH-PREB-1 NVrvN|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW1TWM2OD13LkOyN|EzKM7:TR?= NYKzUHRLW0GQR1XS
HC-1 NYnsV2FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjlWpMzUUN3ME21MlQ{OjlzIN88US=> MVzTRW5ITVJ?
SK-MM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILpbVNKSzVyPUWuOFc5OiEQvF2= NHfQRWRUSU6JRWK=
SH-4 NIr1SmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SzVGlEPTB;NT60PFM4KM7:TR?= M4DkRXNCVkeHUh?=
MHH-CALL-2 NUXmRlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTtTWM2OD13Lke2O|E6KM7:TR?= M1n6N3NCVkeHUh?=
KG-1 NV3WPYk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzkR3FKSzVyPU[uNFI5PzhizszN MVXTRW5ITVJ?
J-RT3-T3-5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n6SGlEPTB;Nj6wO|kxQSEQvF2= NYPRXHk{W0GQR1XS
MMAC-SF NF3hWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZwMUC5OFkh|ryP NVLCTJVpW0GQR1XS
IST-SL2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3reYZ4UUN3ME22MlEzPTF7IN88US=> NVP6Z4hQW0GQR1XS
SW954 NYTvcZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TsOGlEPTB;Nj6yO|UyPyEQvF2= NF3Ue|FUSU6JRWK=
HDLM-2 NGW3TYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DDUWlEPTB;Nj6zNlExQSEQvF2= Mn75V2FPT0WU
ST486 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHFVohKSzVyPU[uN|Q4OSEQvF2= MWPTRW5ITVJ?
DG-75 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\pV2lEPTB;Nj60N|A3QSEQvF2= MX\TRW5ITVJ?
EW-3 NEjWdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZwNEOyNFch|ryP NITwXndUSU6JRWK=
8-MG-BA MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTZwNUG1NFch|ryP NWLKZnd5W0GQR1XS
GT3TKB NFfxb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvPbJFoUUN3ME22MlYxPzZ|IN88US=> NH76cW5USU6JRWK=
KU812 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTZwNkm0NkDPxE1? MlWyV2FPT0WU
CESS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPQVHVWUUN3ME23MlExPDN6IN88US=> M{\LZnNCVkeHUh?=
BC-1 NYTnbm52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPnWWhGUUN3ME23MlI1QDF{IN88US=> MULTRW5ITVJ?
MZ1-PC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTdwM{CzPFkh|ryP MnHYV2FPT0WU
NCI-H82 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOwVJlKSzVyPUeuN|c5PSEQvF2= NXm1TJhvW0GQR1XS
NCI-H1355 M2LuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTdwNEW4NFQh|ryP NVHlVZpIW0GQR1XS
RPMI-8226 NIXNZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCyTWM2OD15LkWwO|M6KM7:TR?= NXzXVYtuW0GQR1XS
ARH-77 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXfXBjUUN3ME23MlU{PTl5IN88US=> NX;YUXRiW0GQR1XS
MN-60 M37TSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXrSoxKSzVyPUeuOVQxQDhizszN NVvjdXExW0GQR1XS
IMR-5 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTdyNUS4O|Yh|ryP Mn;nV2FPT0WU
KARPAS-422 M3X4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwNUeyNFYh|ryP M3rTXXNCVkeHUh?=
CA46 NHjzbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTqTWM2OD15LkW4NFEzKM7:TR?= NXnqbmpNW0GQR1XS
SJSA-1 NFTldpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm0elJKSzVyPUeuOlYxPjFizszN MXPTRW5ITVJ?
no-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LiOGlEPTB;Nz63O|U2PyEQvF2= MYDTRW5ITVJ?
IST-SL1 NVLn[FM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX0cGpKSzVyPUiuNFI1OTdizszN NXLzNVMzW0GQR1XS
NCI-H209 NEXyNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf4eGVCUUN3ME24MlEyPjV{IN88US=> MVrTRW5ITVJ?
TALL-1 M1Lm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\0UGFXUUN3ME24MlE5Ozh2IN88US=> MVTTRW5ITVJ?
KMOE-2 NGXv[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnQcmN7UUN3ME24MlE6PDJizszN NW\FdYEzW0GQR1XS
HCC1599 M3TCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnjPIhkUUN3ME24MlE6QTh5IN88US=> M4T4ZXNCVkeHUh?=
CI-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW5e3JKSzVyPUiuNlA1OTFizszN NFK3e2hUSU6JRWK=
NCI-H1304 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vER2lEPTB;OD6yNFY3OSEQvF2= MnG3V2FPT0WU
Daudi NVnlXoF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRThwMkO1OFYh|ryP NUe0eI5XW0GQR1XS
CPC-N MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRThwMkmxPVkh|ryP MVjTRW5ITVJ?
MC-CAR NFXJXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvrdJhoUUN3ME24MlM{PThizszN NWrNVnIxW0GQR1XS
SW872 NXHOV49qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\ONmtKSzVyPUiuN|Q4PThizszN NIfjfWRUSU6JRWK=
OVCAR-4 NGP6RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fkdWlEPTB;OD61NFM2OSEQvF2= MUXTRW5ITVJ?
OCUB-M MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRThwNU[1NFgh|ryP M3fvSnNCVkeHUh?=
SK-PN-DW NUL0[YF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW2XmhKSzVyPUiuOlA6QDVizszN M{P6b3NCVkeHUh?=
NCCIT NFf2c2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjuTWM2OD16LkexO|Q2KM7:TR?= NYC0e|NNW0GQR1XS
NCI-H1648 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;xfZVoUUN3ME25MlE{QDN2IN88US=> MWTTRW5ITVJ?
COR-L279 NEPUTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTlwM{mwPUDPxE1? MXjTRW5ITVJ?
LS-123 NXn0XFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnpVm9FUUN3ME25MlY5OTZzIN88US=> NHv0Z2NUSU6JRWK=
LP-1 NF3pb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTTfJlvUUN3ME25Mlc5ODh|IN88US=> MkHMV2FPT0WU
NB13 NIPpN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrSTWM2OD17Lke5PVk1KM7:TR?= MUPTRW5ITVJ?
ONS-76 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTlwOEGwNVYh|ryP M3zKcHNCVkeHUh?=
VA-ES-BJ MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;WTlNKSzVyPUmuPVk6OzNizszN NGTMOm5USU6JRWK=
GR-ST MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq0O|k4UUN3ME2xNE4zOjB5IN88US=> NUjBZZA1W0GQR1XS
ES1 NV2yNZpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFyLkK5PFQh|ryP M4Toe3NCVkeHUh?=
NB14 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojKTWM2OD1zMD65Nlc4KM7:TR?= M3PN[nNCVkeHUh?=
Ramos-2G6-4C10 NHXBTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[0O2lEPTB;MUGuNlY2KM7:TR?= NXLhTJF{W0GQR1XS
RXF393 M1Hxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOwZZJKSzVyPUGxMlQ5OzRizszN NGewXmVUSU6JRWK=
NCI-H2107 M1XrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPXTWM2OD1zMT61PVg1KM7:TR?= M{XufHNCVkeHUh?=
K562 M2TKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHXUpFKSzVyPUGxMlg4ODJizszN MXHTRW5ITVJ?
LOUCY M1XUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\MTpNKSzVyPUGxMlk5PzVizszN NIrpVWFUSU6JRWK=
TGBC1TKB NEPufnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HIXGlEPTB;MUKuNFAzKM7:TR?= NGHK[2dUSU6JRWK=
COLO-320-HSR NUHBe2dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomyTWM2OD1zMj6xOVY2KM7:TR?= NXrxeYQ{W0GQR1XS
K5 NGPJSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF{LkK5PFUh|ryP MY\TRW5ITVJ?
BC-3 NUXtUGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XJeGlEPTB;MUKuOFY2OSEQvF2= Mo[5V2FPT0WU
REH Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS5TWM2OD1zMj62OFk5KM7:TR?= MUPTRW5ITVJ?
NEC8 M33JRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PCfGlEPTB;MUKuOlg5PyEQvF2= NF;RVpVUSU6JRWK=
IST-MEL1 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH0SZhKSzVyPUGyMlg3QTRizszN MYrTRW5ITVJ?
NCI-H128 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITYT3NKSzVyPUGzMlA4OjNizszN M3n1RXNCVkeHUh?=
NCI-H1694 NES5[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;m[2lEPTB;MUOuNVE1PCEQvF2= NY\6fZpjW0GQR1XS
TGW MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF|LkOyO|Yh|ryP NHTiOJJUSU6JRWK=
NCI-SNU-1 M2j0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;uTWM2OD1zMz6zOFUh|ryP Mnm2V2FPT0WU
IST-MES1 M1;5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M176UWlEPTB;MUOuOlczQSEQvF2= NXHDV2JnW0GQR1XS
CTB-1 NXfQfHkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2UnFKSzVyPUGzMlczQTRizszN MnLUV2FPT0WU
HUTU-80 NIHpeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF|Lke1O|Mh|ryP MYDTRW5ITVJ?
LAN-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF2LkK0OVch|ryP MXvTRW5ITVJ?
KP-N-YS NIPjdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzD[HQ3UUN3ME2xOE4zQDl2IN88US=> NFS0bplUSU6JRWK=
CCRF-CEM Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DWU2lEPTB;MUSuOFE3QSEQvF2= M3nER3NCVkeHUh?=
NCI-H1770 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2LkWzOlkh|ryP NXXKVFUyW0GQR1XS
MZ2-MEL M4Ts[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF3LkKyOVEh|ryP NEX3[VBUSU6JRWK=
COR-L88 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17yPWlEPTB;MU[uNFAyOiEQvF2= NXP4OI1bW0GQR1XS
LOXIMVI NGXLelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL3UGl1UUN3ME2xOk4zPTZizszN M1XLUHNCVkeHUh?=
KALS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzN[4pKSzVyPUG2MlU6OzFizszN MW\TRW5ITVJ?
D-283MED MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTrXZZKSzVyPUG2Mlg1QDlizszN NWD5fZV4W0GQR1XS
NCI-H719 M1Lsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHRWIRKSzVyPUG2MlkyPjFizszN MWPTRW5ITVJ?
MLMA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjCNml[UUN3ME2xOk46QTB5IN88US=> NW\xe5JYW0GQR1XS
EVSA-T MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPITWM2OD1zNz6wOFg2KM7:TR?= NGH1NmVUSU6JRWK=
SK-N-FI NXjobZlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjmfnE2UUN3ME2xO{43QTF|IN88US=> MlvQV2FPT0WU
NTERA-S-cl-D1 NVnUWFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHhbnBGUUN3ME2xO{45PTd{IN88US=> MnHYV2FPT0WU
NCI-H1882 NI\PWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF5Lkm4N|Qh|ryP NVrZNZhYW0GQR1XS
A704 NYX6dI1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ITWM2OD1zNz65PVA1KM7:TR?= MmTGV2FPT0WU
L-428 NHrlRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITpSmFKSzVyPUG4MlAyPTFizszN M2jDdXNCVkeHUh?=
HCC1187 NV[yXGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DyRmlEPTB;MUiuNFE5PyEQvF2= MWTTRW5ITVJ?
NCI-H1581 M1zsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF6LkC4OlYh|ryP M4f3S3NCVkeHUh?=
BB65-RCC M1G5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq0TWM2OD1zOD60NVYzKM7:TR?= MmGyV2FPT0WU
EM-2 NF\Nb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF6LkW2O|Ih|ryP M4nQb3NCVkeHUh?=
Raji MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DIUGlEPTB;MUmuPVU3PSEQvF2= MnLFV2FPT0WU
TE-1 M2POVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17GVWlEPTB;MkCuOFExPCEQvF2= MUTTRW5ITVJ?
SW962 NG\1fotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M360TWlEPTB;MkCuOFI6OyEQvF2= NHzrVZlUSU6JRWK=
MHH-NB-11 NVK3VIo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJyLkW1NlEh|ryP NGrDe45USU6JRWK=
no-10 NGryZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJzLkCyOlQh|ryP NI\OUm9USU6JRWK=
GDM-1 NXzHZlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHiVG06UUN3ME2yNU46PDF2IN88US=> NETxdJhUSU6JRWK=
KMS-12-PE NVf2VnRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ{LkK3OEDPxE1? NVXsSmt7W0GQR1XS
NCI-H510A M1i0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3YTWM2OD1{ND6xNlc5KM7:TR?= M3fWb3NCVkeHUh?=
ES5 M1;OUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXIZVRKUUN3ME2yOE44OzR7IN88US=> MnH2V2FPT0WU
JiyoyeP-2003 NEHN[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJ4LkK3OFIh|ryP MYfTRW5ITVJ?
NMC-G1 M2LSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK3c3VEUUN3ME2yO{4yQDJ{IN88US=> M2LzOnNCVkeHUh?=
NCI-H446 NVTwSoQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnruTWM2OD1{Nz60PVQ3KM7:TR?= NEX4b3NUSU6JRWK=
NB7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ5LkmyNlkh|ryP M4\pRXNCVkeHUh?=
A388 M3;WTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;YbYs6UUN3ME2yPE4xODd2IN88US=> Ml\2V2FPT0WU
JVM-2 NHHCUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG1OmJKSzVyPUK4MlI5QThizszN MoLhV2FPT0WU
HT-144 NYDwdHNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDBTWM2OD1{OD62PUDPxE1? M37t[XNCVkeHUh?=
NCI-H747 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DJRWlEPTB;MkiuPVE6PSEQvF2= M2XPS3NCVkeHUh?=
NCI-H1650 NW\zc4VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfHXHAxUUN3ME2yPU4xOTd4IN88US=> MXrTRW5ITVJ?
EB-3 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXLdGxkUUN3ME2yPU42OzB7IN88US=> NUHQZ2h{W0GQR1XS
KLE MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTrZm5KSzVyPUK5MlYyQSEQvF2= MlrHV2FPT0WU
TK10 NH3UZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfGTWM2OD1|MD6xNlYh|ryP Ml\TV2FPT0WU
COLO-668 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPyTG5KSzVyPUOwMlc6OiEQvF2= NFHs[m9USU6JRWK=
NCI-H23 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T2PWlEPTB;M{GuNVA3OyEQvF2= NEf6eYFUSU6JRWK=
GOTO NYCzXGZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULMZm03UUN3ME2zNU43ODh3IN88US=> MWPTRW5ITVJ?
MSTO-211H M1PkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3XTWM2OD1|MT64Olc5KM7:TR?= MoHhV2FPT0WU
LB831-BLC NITQVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnP[nJlUUN3ME2zNk4{QDR|IN88US=> NXKzWmh4W0GQR1XS
SCH NHLqO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXqSGt3UUN3ME2zNk45PDh3IN88US=> MUXTRW5ITVJ?
EHEB Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfqZ|VSUUN3ME2zOE4yOTl|IN88US=> MVrTRW5ITVJ?
U-266 M{f1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\ITWM2OD1|ND6yO|gyKM7:TR?= MniwV2FPT0WU
EW-11 NXfDcJByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN2LkS3NlUh|ryP NVHoXIR3W0GQR1XS
TE-9 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXGTWM2OD1|Nz6wOFAyKM7:TR?= MYXTRW5ITVJ?
ES3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN5LkWwNFQh|ryP NEDpco1USU6JRWK=
NCI-H2141 NEPMO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G2OWlEPTB;M{iuNFg1OyEQvF2= NIXsUXNUSU6JRWK=
MPP-89 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XGR2lEPTB;NEKuNFU5PiEQvF2= MXvTRW5ITVJ?
SK-MEL-2 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHlOm97UUN3ME20Nk43PDB3IN88US=> MmHWV2FPT0WU
LC-1F MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LkbmlEPTB;NEOuN|Y5OiEQvF2= MVfTRW5ITVJ?
NH-12 M4[1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LyS2lEPTB;NEOuPVM2QSEQvF2= MlO4V2FPT0WU
RKO NH\3eZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTlTWM2OD12ND6xNlUzKM7:TR?= NX7u[I4{W0GQR1XS
KM-H2 NUjRTI1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR2Lkm1O|ch|ryP MVzTRW5ITVJ?
SK-UT-1 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle2TWM2OD12OT64PFI2KM7:TR?= MWfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02761057 Recruiting Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 2016 Phase 2
NCT02779283 Recruiting Untreated Adult Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) December 2015 Phase 1
NCT02626754 Enrolling by invitation Renal Cell Carcinoma vghtpe user|Taipei Veterans General Hospital, Taiwan August 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT01835158 Active, not recruiting Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer National Cancer Institute (NCI) July 2013 Phase 2
NCT01740154 Terminated Fatigue|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer Case Comprehensive Cancer Center|National Cancer Institute (NCI) September 2012 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID